TrialTargeted oncology2025

Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma.

Mohamed Elmeliegy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.